A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)

Part of paid clinical trials in Denver, Colorado.

Sponsor
Genentech, Inc.
Study ID
NCT00090623
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a phase III, multicenter, randomized, double masked, sham injection-controlled study of the efficacy and safety of intravitreally administered ranibizumab in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration.

Key Dates

First listed
Sep 1, 2004
Start date
Aug 31, 2004
Status verified
Jun 2013
Completion
Mar 31, 2007

Study Design

Enrollment
180 participants
Allocation
RANDOMIZED
Primary purpose
TREATMENT

Locations (1)

FacilityCityStateZIPSite coordinators
Trial Information Support LineDenverColorado--

Find similar trials in Denver, CO

By condition
Age-related macular degeneration
By specialty
OphthalmologyRetina
By research site
Trial Information Support Line· Denver, CO

Related Studies